Richard Starr on Muck Rack

Richard Starr

Washington, D.C.
As seen in: Color Research & Application, Engadget, EIN News, JD Supra, Lexology, Commentary Magazine, JoVE- Journal of Visualized Experiments, Mondaq, Westlaw Today, Fine Woodworking and
Ex @weeklystandard (1995-2018). Aiming for a high signal-to-noise ratio.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Richard

Contact Richard, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

FDA Clears the Way for Bemotrizinol: First New OTC Sunscreen Active Ingredient in More Than 20 Years | JD Supra

|
By Richard Starr
| JD Supra
On June 10, 2026, FDA issued Final Administrative Order OTC000039, adding bemotrizinol (BEMT) to the list of permitted active ingredients in the OTC Sunscreen Monograph (M020). That makes it the first new sunscreen active ingredient added to the U.S. OTC monograph since the late 1990s.
Open in Who Shared Issue with article?

CPG Brands, Meet Your New P&L Line Item: Packaging EPR

|
By Claudia Lewis, Richard Starr
| JD Supra
For years, conversations about large-scale packaging sustainability laws were relegated to the edge of the CPG agenda. But now, Extended Producer Responsibility (EPR) laws are turning packaging into a regulated cost center. For food, supplement, and cosmetic companies, the impact will be felt SKU by SKU, and EPR compliance is not a one-time exercise.
Open in Who Shared Issue with article?

FDA's Latest GLP 1 Crackdown: What Compounders and Telehealth Platforms Need to Know

|
By Claudia Lewis, Richard Starr, Todd Harrison
| Westlaw Today Verified
On March 3, 2026, FDA announced it had issued 30 warning letters to telehealth companies marketing compounded GLP‑1 products whose promotion of compounded GLP‑1s, in FDA's view, implies equivalence to FDA-approved products and/or branding that...
Open in Who Shared Issue with article?
See all 68 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified